Risks listed by the department The advisory enumerates specific risks associated with unauthorized or counterfeit products, including: containing too much, too little, or none of the active ingredient [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized] containing unlisted, dangerous or unknown ingredients [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized] containing contaminants such as solvents, heavy metals, particles, or microbials [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized] being poorly or incorrectly labelled, or improperly manufactured or stored [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized] Health Canada adds that unauthorized injectable products carry additional risks such as infections due to lack of sterility, allergic reactions, and other serious negative outcomes due to contamination, improper handling, or unsafe administration [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized]
license number non-empty and pattern-checked if jurisdiction rules exist)
In a Phase 2 obesity trial of retatrutide published in the New England Journal of Medicine in 2023, nausea, diarrhea, vomiting and constipation were cited as the most common adverse events, with higher doses associated with more severe problems
For CagriSema, there was a 14.4% reduction in lean soft-tissue mass
Risks Of Medication Instability And Contamination Tirzepatide is typically administered in special pens or vials
Dont worry about clearing your plate
